Dabrafenib Mesylate (Standard)
Dabrafenib (Mesylate) (Standard) is the analytical standard of Dabrafenib (Mesylate). This product is intended for research and analytical applications. Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98%
- CAS. Nr.: 1195768-06-9
- Formel: C24H24F3N5O5S3
- Molecular Weight:615.67
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
-
HY-14660
DabrafenibBRAF Inhibitor -
HY-14660A
Dabrafenib MesylateRaf Inhibitor -
HY-10966
SB-590885BRAF/c-Raf Inhibitor -
HY-15605
EncorafenibBRAF Inhibitor -
HY-51424
PLX-4720B-Raf Inhibitor -
HY-15200
AgerafenibBRAF Inhibitor -
HY-15246
TovorafenibRaf Kinase Inhibitor -
HY-11004
AZ 628Apoptosis Inducer -
HY-12057
VemurafenibB-Raf Inhibitor -
HY-50864
GDC-0879B-Raf Inhibitor -
HY-112089
NaporafenibB/CRAF Inhibitor -
HY-10201
SorafenibMultikinase Inhibitor
Product Information
Information
Anwendung
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS. Nr. 1195768-06-9
-
Molecular Weight 615.67
-
Formel C24H24F3N5O5S3
-
SMILES
CC(C)(C)C1=NC(C2=C(F)C(NS(C3=C(F)C=CC=C3F)(=O)=O)=CC=C2)=C(C4=CC=NC(N)=N4)S1.CS(=O)(O)=O
-
Synonyms
GSK2118436 Mesylate (Standard); GSK 2118436B (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920. [Content Brief]
[2]. Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22. [Content Brief]
[3]. Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9. [Content Brief]
[4]. Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405. [Content Brief]
[5]. Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Dabrafenib Mesylate (Standard) Related Classifications
HY-14660AR Related Classifications
Powered by Bioz